Back to Search
Start Over
Supplementary Tables 1-3 from Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Tables 1-3 from Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....2499d916a1350fce24614d682612a471
- Full Text :
- https://doi.org/10.1158/0008-5472.22366653.v1